- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.12.24 | Namandjé Bumpus, FDA's No. 2 official, to depart agency at end of year | ||
| 17.12.24 | Merck targets 2025 RSV season with antibody now under FDA review | ||
| 17.12.24 | Pfizer predicts stability, to Wall Street's relief | ||
| 17.12.24 | Sanofi, Teva say study results show gut disease drug could be 'best in class' | ||
| 16.12.24 | Jazz to search for new chief as CEO plans retirement | ||
| 16.12.24 | Edgewise weighs fast approval path for muscular dystrophy drug | ||
| 16.12.24 | Novo builds up manufacturing; Pepgen Duchenne trial put on hold | ||
| 16.12.24 | Novo Holdings' purchase of Catalent set to close after regulators' green light | ||
| 16.12.24 | Could the gut microbiome hold the key to fighting cancer? | ||
| 16.12.24 | Are we overlooking something critical in cell and gene therapy research? | ||
| 13.12.24 | CMS says private Medicare plans can't automatically deny Biogen's ALS drug | ||
| 13.12.24 | FDA panel seeks more data on RSV vaccine safety in infants | ||
| 13.12.24 | Dietmar Berger is Gilead's new CMO; Padlock investors sue Bristol Myers | ||
| 13.12.24 | AbbVie to acquire Roche spinout Nimble in immune drug deal | ||
| 12.12.24 | Editas to lay off staff after search for sickle cell partner comes up empty | ||
| 12.12.24 | FDA flags additional injury risk for Intercept's liver drug | ||
| 12.12.24 | 'Research that's desperately needed': White House conference spotlights women's health | ||
| 12.12.24 | Keros shares collapse on 'unanticipated' setback for lung disease drug | ||
| 11.12.24 | GLP-1 drug compounding is in limbo. Will the FDA draw out its decision? | ||
| 11.12.24 | With new data, Lilly sets pace for next wave of breast cancer drugs | ||
| 11.12.24 | Q32 Bio battered by study failure of immune drug | ||
| 11.12.24 | BenevolentAI restructures; Lilly preps $15B buyback program | ||
| 11.12.24 | Chroma, Nvelop merge to marry genetic medicine 'cargo' to delivery | ||
| 10.12.24 | ASH24: Leukemia drug sequencing, sickle cell questions and a new kind of CAR-T | ||
| 10.12.24 | UniQure shares soar on chance of speedy approval for Huntington's therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
